Publications — Semenov Lab | Harvard Dermatology AI Research

Melanoma recurrence ROC curves — AUROC 0.845 internal, 0.812 external — Melanoma ML ROC curves — AUROC 0.845 internal, 0.812 external · *Wan et al., npj Precision Oncology 2022*

Cutaneous irAE incidence rate ratios · *Wongvibulsin, …, Semenov, JAAD 2022*

Updated September 19, 2026; preprints excluded. Newest first by PubMed publication date (including online-first records).

J Am Acad Dermatol2026 Sep 9New

Refining the Definition of Acral Melanoma: Histologic and Anatomic Considerations

Beagles E, Khattab S, Burke OM, et al. (including Semenov YR)

View Article

J Am Acad Dermatol2026 Sep 9New

Prior Keratinocyte Carcinoma as a Risk Factor for Mucosal Melanoma: A Multi-Institutional Retrospective Case-Control Study of Veterans and Civilians in the Veterans Health Administration and Mass General Brigham

Huhmann LB, Hwang JC, Lu C, et al. (including Semenov YR)

View Article

JAMA Dermatol2026 Sep 1New

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma

Lee E, Karagenova R, Lu C, et al. (including Semenov YR)

View Article

J Invest Dermatol 2026 Sep

Incubating artificial intelligence initiatives and careers in dermatology

Wongvibulsin S, Primiero CA, Adamson AS, et al. (including Semenov YR)

View Article

Int J Dermatol2026 SepNew

Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity

Repetto F, Jobbagy S, Lee E, et al. (including Semenov Y)

View Article

J Am Acad Dermatol 2026 Jul

Risk and protective factors for uveal melanoma: Evidence for a protective role of autoimmune and immune-mediated conditions

Lu C, Cheng D, Mu A, et al. (including Semenov YR)

View Article

J Am Acad Dermatol2026 Jun 24New

Nemolizumab for treatment-refractory cutaneous adverse events in patients with cancer: A retrospective multi-institutional case series

Karagenova R, Lee E, Fuksman L, et al. (including Semenov YR)

View Article

J Immunother Cancer2026 Jun 19New

Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events

Lee E, Karagenova R, Fuksman L, et al. (including Semenov YR)

View Article

JAMA Dermatol 2026 Jun 1

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma

Said JT, Li Y, Sadeghi N, et al. (including Semenov YR)

View Article

JAAD IntOnline May 29, 2026 · October 2026 issueNew

Risk factors for the development of acral melanoma: A multi-institutional, retrospective cohort study

Lu C, Burke O, Thang CJ, et al. (including Semenov YR)

View Article

JAMA Netw Open 2026 May 1

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

Wan G, Nguyen N, Lu C, et al. (including Semenov YR)

PDF View Article

JCI Insight 2026 Apr 22

Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis

Rajeh A, Shahsavari S, Cornman H, et al. (including Semenov YR)

View Article

Br J Dermatol 2026 Apr 17

Impact of clinicopathological features on prognosis of thin melanomas: a retrospective cohort analysis

Beagles E, Khattab S, Burke OM, et al. (including Semenov YR)

View Article

JAAD Int 2026 Jun

Development and validation of the Oxford Attitudes to Artificial Intelligence in Medicine Scale

Kantor J, Morrison M, Ko J, Semenov YR, Fortgang RG

View Article

JAMA Dermatol 2026 Mar 1

Identification of Risk Factors for Acral Melanoma in US Veterans

Hwang JC, Huhmann LB, Cho K, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2026 Feb

Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: A retrospective cohort study using the TriNetX database

Khattab S, Chang CT, Shaw KS, et al. (including Semenov YR)

View Article

JAMA Dermatol 2025 Dec 1

Validating the Use of ICD-10 Codes for Identifying Vitiligo

Cheng D, Sanchez K, Biba U, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2025 Dec

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

Azin M, Farokh P, McGarry A, et al. (including Semenov YR)

PDF View Article

NPJ Digit Med 2025 Nov 25

Academia loses its grip on digital health solutions as innovation in artificial intelligence shifts towards industry

Hijaz BA, Burke OM, Khattab SY, Semenov YR

View Article

TMLR 2025 Nov Lab-member publication

Multi-Modal Foundation Models for Computational Pathology: A Survey

Li D, Wan G, Wu X, et al.

View Article

Dermatol Clin 2025 Oct

The Current State and Future Prospects for Artificial Intelligence in Dermatology

Thang CJ, Duffy C, Khattab S, Semenov YR

PDF View Article

JAAD Int 2026 Feb

Quantifying the risk of drug-associated skin hyperpigmentation relative to the general population: A national cohort study using TriNetX

Cheng D, Ji H, Xiang D, et al. (including Semenov YR)

View Article

Int J Dermatol 2025 Sep

Double Trouble: A Case Series on Dual Morphology Cutaneous Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors

Ebriani J, Westmeijer M, Brumbaugh B, et al. (including Semenov YR)

View Article

JAAD Int 2025 Dec

Exposure to intravenous immunoglobulin is associated with increased mortality in patients on immune checkpoint inhibitors: A population-based cohort study

Cheng D, Nguyen NTT, Thang CJ, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2025 Aug

Clinicopathologic attributes and downstream outcomes of mucosal melanomas: A multihospital cohort study

Khattab S, Beagles E, Tran M, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2025 Jul

Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multicenter retrospective cohort study

Hijaz BA, Braun N, Reynolds KL, Semenov YR, LeBoeuf NR, Chen ST

View Article

J Eur Acad Dermatol Venereol 2025 Jul

Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors

Rajeh A, Roster K, Reynolds KL, et al. (including Semenov YR)

View Article

Nat Commun 2025 Jun 27

Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens

Huang M, Wang D, Huang J, et al. (including Semenov YR)

View Article

J Proteomics 2025 May 30

Comprehensive biobanking strategy with clinical impact at the European Cancer Moonshot Lund Center

Oskolas H, Nogueira FCN, Domont GB, et al. (including Semenov YR)

View Article

J Immunother Cancer 2025 May 12

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Khattab S, Wan G, Xu S, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2025 Apr

A retrospective cohort study of the time between prior antibiotics and checkpoint inhibitors and association with survival in melanoma patients

Hirner JP, Rajeh A, Semenov YR, Kwatra SG, LeBoeuf NR

View Article

Med 2025 Mar 14

Precision phenotyping for curating research cohorts of patients with unexplained post-acute sequelae of COVID-19

Azhir A, Hügel J, Tian J, et al. (including Semenov YR)

View Article

J Eur Acad Dermatol Venereol 2025 Mar

Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis

Rajeh A, Roster K, Nguyen N, Leung BW, Rashdan H, Semenov YR

View Article

J Invest Dermatol 2025 Feb

Geotemporal Analysis of Melanoma Incidence and Mortality Identifies Distinct Clusters of Trends within the United States Between 2001 and 2019

Latoni DI, Geller AC, Semenov YR, Ji Z, Tsao H

View Article

JID Innov 2025 Jan

Langerhans Cells Directly Interact with Resident T Cells in the Human Epidermis

Oka T, Hasegawa T, Lee T, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2024 Nov

Differential time series analysis shows deceleration in melanoma mortality prior to the widespread use of highly effective therapies

Latoni DI, Semenov YR, Tsao H

View Article

Hematol Oncol Clin North Am 2024 Oct

Cutaneous Imaging Techniques

Khattab SY, Hijaz BA, Semenov YR

View Article

Br J Dermatol 2024 Aug 14

De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study

Tang K, Rajeh A, Shaw KS, et al. (including Semenov YR)

View Article

Lancet Oncol 2024 Aug

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study

Wan G, Chen W, Khattab S, et al. (including Semenov YR)

PDF View Article

Clin Transl Med 2024 Jul

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma

Pinto de Almeida N, Jánosi ÁJ, Hong R, et al. (including Semenov YR)

View Article

Br J Dermatol 2024 Jun 20

Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study

Wan G, Khattab S, Leung BW, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2024 Jun

Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study

Reardon RM, Perlman KL, Asdourian MS, et al. (including Semenov YR)

View Article

Nat Commun 2024 May 30

Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression

Park JH, Mortaja M, Son HG, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2024 May

Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study

Rashdan H, Zhang S, Wan G, et al. (including Semenov YR)

View Article

J Immunother Cancer 2024 Apr 10

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Chen ST, Semenov YR, Alloo A, et al.

PDF View Article

JAMA Dermatol 2024 Apr 1 Viewpoint

Adjuvant Immunotherapy in Stage II Melanoma-Further Risk Stratification is Needed

Rashdan H, Adamson AS, Semenov YR

PDF View Article

Brief Bioinform 2024 Mar 27

SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data

Wan G, Maliga Z, Yan B, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2024 Mar

Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center

Le TK, Newland ES, Brown I, Goldberg R, Semenov YR, Kwatra SG

PDF View Article

J Am Acad Dermatol 2024 Feb

Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Wan G, Nguyen N, Leung BW, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2024 Feb

Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma

Wan G, Leung BW, DeSimone MS, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2024 Jan

Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study

Roster K, Rajeh A, Nguyen N, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Dec

Recurrence and survival in early-stage acral lentiginous melanoma: A retrospective analysis

Roster K, Rajeh A, Wu F, et al. (including Semenov YR)

PDF View Article

J Invest Dermatol 2023 Dec

A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis

Vasavda C, Wan G, Szeto MD, et al. (including Semenov YR)

View Article

J Drugs Dermatol 2023 Nov 1

Seasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris

Young K, Pagan AD, Yoon J, et al. (including Semenov YR)

View Article

JAMA Dermatol 2023 Nov 1

Use of 3-Dimensional Stereophotogrammetry to Detect Disease Progression in Craniofacial Morphea

Shaw KS, Nguyen TT, Rajeh A, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Oct

Underuse of sentinel lymph node biopsy for early-stage melanoma

Rajeh A, Wan G, Roster K, et al. (including Semenov YR)

PDF View Article

Immunol Rev 2023 Sep

Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash"

Allais BS, Fay CJ, Kim DY, Semenov YR, LeBoeuf NR

View Article

J Drugs Dermatol 2023 Aug 1

Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study

Klebanov N, Pahalyants V, Said JT, et al. (including Semenov YR)

View Article

Arch Dermatol Res 2023 Aug

Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses

Gopinath S, Sutaria N, Bordeaux ZA, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Jul

Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma

Stephens MR, Asdourian MS, Jacoby TV, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2023 Jun

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

Leung BW, Wan G, Nguyen N, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2023 Jun

Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy

Nguyen N, Wan G, Ugwu-Dike P, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2023 Jun

Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy

Asdourian MS, Jacoby TV, Shah N, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 May

Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study

Leung BW, Collier MR, Tiu BC, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 May

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study

Zhang S, Tang K, Wan G, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2023 Apr

Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups in patients with acne vulgaris: A national US retrospective study

Young K, Pagan AD, Yoon J, et al. (including Semenov YR)

View Article

Arch Dermatol Res 2023 Mar

A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020

Parthasarathy V, Pollock JR, McNeely GL, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Feb

Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade

Asdourian MS, Shah N, Jacoby TV, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Feb

Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study

Asdourian MS, Jacoby TV, Shah N, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2023 Jan

Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy

Asdourian MS, Shah N, Jacoby TV, et al. (including Semenov YR)

View Article

Nat Med 2022 Dec

Germline variants associated with toxicity to immune checkpoint blockade

Groha S, Alaiwi SA, Xu W, et al. (including Semenov Y)

PDF View Article

JAMA Dermatol 2022 Dec 1

Validation of Case Identification for Melasma Using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision Codes

Theodosakis N, Yoon J, Young K, Getachew E, Mostaghimi A, Semenov YR

View Article

J Invest Dermatol 2022 Nov

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Le TK, Brown I, Goldberg R, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Nov

Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma

Asdourian MS, Otto TS, Jacoby TV, et al. (including Semenov YR)

View Article

NPJ Precis Oncol 2022 Oct 31

Prediction of early-stage melanoma recurrence using clinical and histopathologic features

Wan G, Nguyen N, Liu F, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Oct

Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis

Raval NS, Hodges WT, Ugwu-Dike PO, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2022 Sep

Understanding racial disparities in prurigo nodularis

Sutaria N, Semenov YR, Kwatra SG

PDF View Article

J Invest Dermatol 2022 Sep

Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis

Sutaria N, Alphonse MP, Roh YS, et al. (including Semenov YR)

View Article

JAAD Int 2023 Mar

The impact of stage-related features in melanoma recurrence prediction: A machine learning approach

Wan G, Leung B, Nguyen N, et al. (including Semenov YR)

PDF View Article

JAAD Int 2022 Dec

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration

Chen W, Wan G, Nguyen N, et al. (including Semenov YR)

PDF View Article

J Natl Cancer Inst 2022 Aug 8

Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy

Tang K, Tiu BC, Wan G, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Aug

Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis

Roh YS, Marani M, Choi U, et al. (including Semenov YR)

View Article

JAMA Dermatol 2022 Jul 1

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus

Deng J, Parthasarathy V, Adawi W, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2022 Jul

Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated"

Pahalyants V, Murphy WS, Klebanov N, et al. (including Semenov YR)

View Article

J Immunother Cancer 2022 Jun

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

Tiu BC, Zubiri L, Iheke J, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Jun

Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012-2017 National Inpatient Sample

Choi J, Sutaria N, Roh YS, et al. (including Semenov YR)

View Article

JAMA Dermatol 2022 May 1

Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors

Said JT, Liu M, Talia J, et al. (including Semenov YR)

PDF View Article

Br J Dermatol 2022 May

Latent class analysis identification of prurigo nodularis comorbidity phenotypes

Wongvibulsin S, Parthasarathy V, Pahalyants V, et al. (including Semenov YR)

View Article

J Invest Dermatol 2022 May

Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans

Sutaria N, Alphonse MP, Marani M, et al. (including Semenov YR)

View Article

J Dermatolog Treat 2022 May

Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses

Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG

PDF View Article

J Am Acad Dermatol 2022 Mar

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Wongvibulsin S, Pahalyants V, Kalinich M, et al. (including Semenov YR)

PDF View Article

J Dermatol Sci 2022 Feb

Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis

Sutaria N, Marani M, Choi J, et al. (including Semenov YR)

View Article

JAMA Dermatol 2022 Feb 1

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy

Tang K, Seo J, Tiu BC, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Feb

Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study

Sutaria N, Adawi W, Brown I, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2022 Jan

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts

Pahalyants V, Murphy WS, Klebanov N, et al. (including Semenov YR)

View Article

Cancers (Basel)2021 Dec 1

An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation

Gil J, Rezeli M, Lutz EG, et al. (including Semenov YR)

View Article

Genome Med2021 Nov 8

Constructing germline research cohorts from the discarded reads of clinical tumor sequences

Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N

View Article

J Invest Dermatol 2021 Oct

A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States

Wongvibulsin S, Sutaria N, Williams KA, et al. (including Semenov YR)

View Article

BMC Med 2021 Sep 27

Evolving phenotypes of non-hospitalized patients that indicate long COVID

Estiri H, Strasser ZH, Brat GA, et al. (including Semenov YR)

View Article

J Immunother Cancer 2021 Sep

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

Zubiri L, Molina GE, Mooradian MJ, et al. (including Semenov YR)

View Article

Br J Dermatol 2021 Sep

Itch in skin of colour: a multicentre cross-sectional study

Sutaria N, Parthasarathy V, Roh YS, et al. (including Semenov YR)

View Article

Dermatol Surg 2021 Aug 1

Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis

Zhang J, Erickson S, Semenov YR, Council ML

View Article

J Am Acad Dermatol 2021 Aug

Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey

Semenov YR, Herbosa CM, Rogers AT, et al.

PDF View Article

J Am Acad Dermatol 2021 Aug

Health-related quality of life in patients with malignant melanoma by stage and treatment status

Rosenberg AR, Weston SJ, Deshields T, et al. (including Semenov YR)

View Article

Br J Dermatol 2021 Jul

Biologics utilization for psoriasis is lower in black compared with white patients

Hodges WT, Bhat T, Raval NS, et al. (including Semenov YR)

View Article

Oncologist 2021 Jun

Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018

Molina GE, Zubiri L, Cohen JV, et al. (including Semenov YR)

View Article

Oncologist 2021 May

Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Klebanov N, Pahalyants V, Murphy WS, et al. (including Semenov YR)

View Article

J Am Acad Dermatol 2021 May

Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019

Phelan PS, Semenov YR, Nahmias ZP

View Article

J Immunother Cancer 2021 Mar

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA

Kalinich M, Murphy W, Wongvibulsin S, et al. (including Semenov YR)

PDF View Article

J Am Acad Dermatol 2021 Mar

Ethnic variations in scalp pruritus and hair loss

Osemwota O, Herbosa CM, Zhong C, Kwatra SG, Kim BS, Semenov YR

View Article

Br J Dermatol 2021 Feb

Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma

Bhat TS, Herbosa CM, Rosenberg AR, et al. (including Semenov YR)

View Article

J Clin Aesthet Dermatol 2020 Nov

A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma

Kwatra SG, Hines H, Semenov YR, Trotter SC, Holland E, Leachman S

View Article

Int J Womens Dermatol 2020 Dec

Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections: A single-center retrospective study

Herbosa CM, Bhat TS, Semenov YR, Rosman IS, Musiek AC

View Article

J Eur Acad Dermatol Venereol 2020 Sep

Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a single-institution cohort

Herbosa CM, Hodges W, Mann C, Demehri S, Cornelius LA, Semenov YR

PDF View Article

Medicines (Basel) 2020 Aug 28

Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study

Almazan E, Roh YS, Belzberg M, et al. (including Semenov YR)

View Article

J Eur Acad Dermatol Venereol 2020 May

Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments

Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC

View Article

Int J Pediatr Otorhinolaryngol 2020 Mar

Association between vertigo, cognitive and psychiatric conditions in US children: 2012 National Health Interview Survey

Bigelow RT, Semenov YR, Hoffman HJ, Agrawal Y

PDF View Article

Br J Dermatol 2020 Jan

Health-related quality of life and economic implications of cutaneous T-cell lymphoma

Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC

PDF View Article

Medicines (Basel) 2019 Dec 9

Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists

Kwatra SG, Boozalis E, Huang AH, et al. (including Semenov YR)

PDF View Article

J Natl Med Assoc 2019 Dec

Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides

Huang AH, Kwatra SG, Khanna R, Semenov YR, Okoye GA, Sweren RJ

View Article

J Rheumatol 2019 Jun

Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey

Semenov YR, Hsiang EY, Huang A, et al.

View Article

J Am Acad Dermatol 2018 Oct

Ethnic differences and comorbidities of 909 prurigo nodularis patients

Boozalis E, Tang O, Patel S, et al. (including Semenov YR)

View Article

J Dermatolog Treat 2018 Sep

Food and drug administration approval process for dermatology drugs in the United States

Boozalis E, Semenov YR, Kwatra SG

View Article

J Dermatolog Treat 2018 May

Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005-2014

Rogers AT, Semenov YR, Kwatra SG, Okoye GA

View Article

Br J Dermatol 2018 Apr

Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016

Hsiang EY, Semenov YR, Aguh C, Kwatra SG

View Article

Laryngoscope Investig Otolaryngol 2018 Feb

Health-related quality of life and economic burden of vestibular loss in older adults

Agrawal Y, Pineault KG, Semenov YR

View Article

J Am Acad Dermatol 2017 Mar

Seasonal variation of itch: A study using real-time data from 2004 to 2016

Grandhi R, He A, Semenov YR, Kwatra SG

PDF View Article

Audiol Neurootol 2017

Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review

Crowson MG, Semenov YR, Tucci DL, Niparko JK

PDF View Article

J Assoc Res Otolaryngol 2016 Oct

Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging

Bigelow RT, Semenov YR, Anson E, du Lac S, Ferrucci L, Agrawal Y

PDF View Article

J Neurol Neurosurg Psychiatry 2016 Apr

Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey

Bigelow RT, Semenov YR, du Lac S, Hoffman HJ, Agrawal Y

PDF View Article

J Gerontol A Biol Sci Med Sci 2016 Feb

Association Between Vestibular and Cognitive Function in U.S. Adults: Data From the National Health and Nutrition Examination Survey

Semenov YR, Bigelow RT, Xue QL, du Lac S, Agrawal Y

PDF View Article

Otol Neurotol 2015 Sep

The Role of Obliteration in the Achievement of a Dry Mastoid Bowl

Harun A, Clark J, Semenov YR, Francis HW

View Article

J Am Geriatr Soc 2015 Sep

Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging

Bigelow RT, Semenov YR, Trevino C, et al.

PDF View Article

Gerontol Geriatr Med 2015 Jan-Dec

Vestibular Function and Activities of Daily Living: Analysis of the 1999 to 2004 National Health and Nutrition Examination Surveys

Harun A, Semenov YR, Agrawal Y

PDF View Article

JAMA Otolaryngol Head Neck Surg 2014 Jun

Bilateral Vestibular Deficiency: Quality of Life and Economic Implications

Sun DQ, Ward BK, Semenov YR, Carey JP, Della Santina CC

View Article

Ear Hear 2013 Jul-Aug

Age-dependent cost-utility of pediatric cochlear implantation

Semenov YR, Yeh ST, Seshamani M, et al.

PDF View Article

Otolaryngol Head Neck Surg 2013 Apr

Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery

Chan JY, Semenov YR, Gourin CG

PDF View Article

Otolaryngol Clin North Am 2012 Oct

Cochlear implants: clinical and societal outcomes

Semenov YR, Martinez-Monedero R, Niparko JK

PDF View Article

Laryngoscope 2012 Oct

The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery

Hennessey P, Semenov YR, Gourin CG

PDF View Article

Laryngoscope 2012 Sep

The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery

Semenov YR, Starmer HM, Gourin CG

PDF View Article